Morgensztern, D., Govindan, R., Cobo, M., Ponce Aix, S., Postmus, P., Lewanski, C., . . . Ong, T. (2018). Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+). Elsevier.
Chicago-referens (17:e uppl.)Morgensztern, D., et al. Efficacy and Safety of Second- or Third-line Nab-paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+). Elsevier, 2018.
MLA-referens (9:e uppl.)Morgensztern, D., et al. Efficacy and Safety of Second- or Third-line Nab-paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+). Elsevier, 2018.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.